@article{oai:gifu-pu.repo.nii.ac.jp:00012042,
 author = {KURIMOTO, Tsukasa and ASAKA, Naomasa and MAEDA, Toshimatsu and IRIMURA, Kenji and MATSUURA, Naosuke},
 journal = {岐阜藥科大學紀要, The annual proceedings of Gifu College of Pharmacy},
 month = {Jun},
 note = {P(論文), MET-88,an inhibitor of γ-butyrobetaine hydroxylase, can be characterized as a unique cardioprotective agent for the treatment of congestive heart failure (CHF) with an ability to regulate the activity of SR Ca^<2+>-ATPase. MET-88 protected the hypoxic and ischemic myocardium due to the modulation of myocardial metabolism and improved cardiac remodeling and hypertrophy as effectively as captopril. MET-88 also increased the failed Ca^<2+>-ATPase activity in the Sarcoplastic reticulum (SR), which increase might have resulted from ATP synthesis through glycolysis. These effects of MET-88 may be expected to improve mortality, prognosis, and exercise intolerance in CHF patients. In summary, MET-88 may be a useful drug for the treatment of CHF.},
 pages = {45--52},
 title = {<Review>MET-88 : Sarcoplastic Reticulum Ca^<2+>-Uptake Stiumlator for Treating Chronic Heart Failure},
 volume = {49},
 year = {2000}
}